Danielle Antalffy
Stock Analyst at UBS
(3.76)
# 2,055
Out of 4,690 analysts
604
Total ratings
51.3%
Success rate
3.4%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Reiterated: Hold | $22 → $18 | $22.72 | -20.77% | 28 | Aug 7, 2026 | |
| ABT Abbott Laboratories | Reiterated: Buy | $158 → $135 | $111.25 | +21.35% | 38 | Apr 20, 2026 | |
| BSX Boston Scientific | Rated: Buy | $120 → $105 | $51.83 | +102.59% | 42 | Mar 17, 2026 | |
| ISRG Intuitive Surgical | Rated: Hold | $570 → $550 | $394.51 | +39.41% | 10 | Mar 17, 2026 | |
| JNJ Johnson & Johnson | Rated: Buy | $214 → $280 | $260.35 | +7.55% | 34 | Mar 17, 2026 | |
| SYK Stryker | Rated: Hold | $400 → $380 | $339.21 | +12.03% | 20 | Mar 17, 2026 | |
| SGHT Sight Sciences | Rated: Buy | $12 → $11 | $8.14 | +35.14% | 6 | Mar 6, 2026 | |
| TMCI Treace Medical Concepts | Maintained: Hold | $2.5 → $2.25 | $4.79 | -53.03% | 15 | Mar 2, 2026 | |
| PRCT PROCEPT BioRobotics | Maintained: Buy | $62 → $30 | $21.65 | +38.57% | 9 | Mar 2, 2026 | |
| RXST RxSight | Maintained: Hold | $8 → $9 | $6.89 | +30.62% | 11 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $400 | $143.34 | +179.06% | 43 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $58 → $55 | $44.30 | +24.15% | 26 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $17.57 | +36.60% | 2 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $104 | $91.27 | +13.95% | 40 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $21 → $19 | $26.73 | -28.92% | 26 | Feb 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $95 | $89.75 | +5.85% | 40 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $89 → $67 | $57.10 | +17.34% | 21 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $94 → $90 | $91.60 | -1.75% | 42 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $86 → $89 | $100.65 | -11.57% | 18 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $24.86 | -3.46% | 1 | Feb 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $145 → $150 | $184.53 | -18.71% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $57 → $50 | $26.06 | +91.86% | 3 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16 → $16 | $15.15 | +5.61% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $2.25 | $8.84 | n/a | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 | $100.95 | n/a | 10 | May 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $14.77 | n/a | 11 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $1.79 | n/a | 6 | May 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $8.20 | n/a | 5 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $275 | $183.40 | n/a | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $55 | $4.51 | n/a | 10 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $44.20 | n/a | 14 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 → $14 | $48.73 | n/a | 6 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $0.3999 | n/a | 14 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $5.75 | n/a | 20 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2 → $3 | $7.81 | n/a | 14 | Aug 9, 2021 |
Tandem Diabetes Care
Aug 7, 2026
Reiterated: Hold
Price Target: $22 → $18
Current: $22.72
Upside: -20.77%
Abbott Laboratories
Apr 20, 2026
Reiterated: Buy
Price Target: $158 → $135
Current: $111.25
Upside: +21.35%
Boston Scientific
Mar 17, 2026
Rated: Buy
Price Target: $120 → $105
Current: $51.83
Upside: +102.59%
Intuitive Surgical
Mar 17, 2026
Rated: Hold
Price Target: $570 → $550
Current: $394.51
Upside: +39.41%
Johnson & Johnson
Mar 17, 2026
Rated: Buy
Price Target: $214 → $280
Current: $260.35
Upside: +7.55%
Stryker
Mar 17, 2026
Rated: Hold
Price Target: $400 → $380
Current: $339.21
Upside: +12.03%
Sight Sciences
Mar 6, 2026
Rated: Buy
Price Target: $12 → $11
Current: $8.14
Upside: +35.14%
Treace Medical Concepts
Mar 2, 2026
Maintained: Hold
Price Target: $2.5 → $2.25
Current: $4.79
Upside: -53.03%
PROCEPT BioRobotics
Mar 2, 2026
Maintained: Buy
Price Target: $62 → $30
Current: $21.65
Upside: +38.57%
RxSight
Feb 26, 2026
Maintained: Hold
Price Target: $8 → $9
Current: $6.89
Upside: +30.62%
Feb 19, 2026
Reiterated: Buy
Price Target: $400
Current: $143.34
Upside: +179.06%
Feb 18, 2026
Maintained: Buy
Price Target: $58 → $55
Current: $44.30
Upside: +24.15%
Feb 18, 2026
Reiterated: Buy
Price Target: $24
Current: $17.57
Upside: +36.60%
Feb 17, 2026
Maintained: Hold
Price Target: $104
Current: $91.27
Upside: +13.95%
Feb 16, 2026
Maintained: Hold
Price Target: $21 → $19
Current: $26.73
Upside: -28.92%
Feb 13, 2026
Reiterated: Buy
Price Target: $95
Current: $89.75
Upside: +5.85%
Feb 13, 2026
Maintained: Hold
Price Target: $89 → $67
Current: $57.10
Upside: +17.34%
Feb 12, 2026
Maintained: Hold
Price Target: $94 → $90
Current: $91.60
Upside: -1.75%
Feb 11, 2026
Maintained: Sell
Price Target: $86 → $89
Current: $100.65
Upside: -11.57%
Feb 9, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $24.86
Upside: -3.46%
Jan 28, 2026
Maintained: Buy
Price Target: $145 → $150
Current: $184.53
Upside: -18.71%
Jan 5, 2026
Maintained: Buy
Price Target: $57 → $50
Current: $26.06
Upside: +91.86%
Nov 6, 2025
Maintained: Hold
Price Target: $16 → $16
Current: $15.15
Upside: +5.61%
Mar 28, 2023
Initiated Coverage: Hold
Price Target: $2.25
Current: $8.84
Upside: n/a
May 17, 2022
Reiterated: Buy
Price Target: $100
Current: $100.95
Upside: n/a
May 12, 2022
Maintained: Buy
Price Target: $12
Current: $14.77
Upside: n/a
May 10, 2022
Maintained: Buy
Price Target: $13
Current: $1.79
Upside: n/a
May 9, 2022
Maintained: Buy
Price Target: $12
Current: $8.20
Upside: n/a
May 5, 2022
Rated: Hold
Price Target: $275
Current: $183.40
Upside: n/a
May 5, 2022
Rated: Buy
Price Target: $65 → $55
Current: $4.51
Upside: n/a
May 4, 2022
Reiterated: Buy
Price Target: $45
Current: $44.20
Upside: n/a
May 4, 2022
Reiterated: Buy
Price Target: $12 → $14
Current: $48.73
Upside: n/a
May 3, 2022
Rated: Buy
Price Target: $5
Current: $0.3999
Upside: n/a
Jan 10, 2022
Maintained: Hold
Price Target: n/a
Current: $5.75
Upside: n/a
Aug 9, 2021
Reiterated: Hold
Price Target: $2 → $3
Current: $7.81
Upside: n/a